$PLSE
Pulse Biosciences Inc

2022 Q4 Form 10-Q Financial Statement

#000162510122000067 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $700.0K $0.00 $574.0K
YoY Change -17.06% -100.0%
Cost Of Revenue $11.94M $8.400M $727.0K
YoY Change 862.45% 1055.43%
Gross Profit -$11.24M -$8.400M -$153.0K
YoY Change 2732.24% 5390.2%
Gross Profit Margin -1606.29% -26.66%
Selling, General & Admin $25.97M $5.108M $7.660M
YoY Change 177.65% -33.32% 32.76%
% of Gross Profit
Research & Development $20.84M $4.517M $6.460M
YoY Change 268.31% -30.08% -7.29%
% of Gross Profit
Depreciation & Amortization $336.0K $200.0K $100.0K
YoY Change 13.13% 100.0% 0.0%
% of Gross Profit
Operating Expenses $46.81M $4.517M $6.460M
YoY Change 211.82% -30.08% -49.94%
Operating Profit -$58.06M -$18.03M -$14.27M
YoY Change 276.75% 26.29% 10.6%
Interest Expense -$448.0K -$14.00K -$9.000K
YoY Change 7366.67% 55.56% -200.0%
% of Operating Profit
Other Income/Expense, Net -$14.00K -$9.000K
YoY Change 55.56% -200.0%
Pretax Income -$58.51M -$18.04M -$14.28M
YoY Change 279.51% 26.31% 10.71%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$58.51M -$18.04M -$14.30M
YoY Change 279.51% 26.15% 10.89%
Net Earnings / Revenue -8357.86% -2491.29%
Basic Earnings Per Share -$0.49 -$0.48
Diluted Earnings Per Share -$1.72 -$0.49 -$482.3K
COMMON SHARES
Basic Shares Outstanding 37.23M 37.13M 29.61M
Diluted Shares Outstanding 37.16M 29.61M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.14M $69.16M $41.99M
YoY Change 113.67% 64.71% 41.91%
Cash & Equivalents $61.14M $69.16M $41.99M
Short-Term Investments $0.00
Other Short-Term Assets $1.008M $1.244M $2.866M
YoY Change -52.7% -56.59% 282.13%
Inventory $0.00 $750.0K $4.281M
Prepaid Expenses
Receivables $0.00 $5.000K $72.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $62.15M $71.16M $49.21M
YoY Change 69.66% 44.61% 62.23%
LONG-TERM ASSETS
Property, Plant & Equipment $1.961M $2.286M $2.446M
YoY Change -20.35% -6.54% -4.53%
Goodwill $2.791M $2.791M $2.791M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $365.0K $365.0K $365.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $15.73M $16.41M $17.94M
YoY Change -10.72% -8.52% -7.35%
TOTAL ASSETS
Total Short-Term Assets $62.15M $71.16M $49.21M
Total Long-Term Assets $15.73M $16.41M $17.94M
Total Assets $77.88M $87.57M $67.15M
YoY Change 43.55% 30.41% 35.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.573M $2.022M $2.706M
YoY Change -45.83% -25.28% 88.97%
Accrued Expenses $2.595M $3.982M $4.971M
YoY Change -40.87% -19.9% 20.92%
Deferred Revenue $0.00 $38.00K $7.000K
YoY Change -100.0% 442.86%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $917.0K $98.00K $1.086M
YoY Change 110.32% -90.98%
Total Short-Term Liabilities $5.981M $6.998M $9.519M
YoY Change -29.79% -26.48% 58.65%
LONG-TERM LIABILITIES
Long-Term Debt $65.00M $65.00M $0.00
YoY Change
Other Long-Term Liabilities $9.144M $9.383M $10.24M
YoY Change -8.92% -8.39% -6.81%
Total Long-Term Liabilities $74.14M $74.38M $10.24M
YoY Change 638.49% 626.25% -6.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.981M $6.998M $9.519M
Total Long-Term Liabilities $74.14M $74.38M $10.24M
Total Liabilities $80.13M $81.38M $19.76M
YoY Change 331.73% 311.83% 16.3%
SHAREHOLDERS EQUITY
Retained Earnings -$294.7M -$285.5M -$220.8M
YoY Change 24.77% 29.31% 39.04%
Common Stock $292.5M $291.7M $268.2M
YoY Change 7.56% 8.77% 40.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.248M $6.189M $47.39M
YoY Change
Total Liabilities & Shareholders Equity $77.88M $87.57M $67.15M
YoY Change 43.55% 30.41% 35.12%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$58.51M -$18.04M -$14.30M
YoY Change 279.51% 26.15% 10.89%
Depreciation, Depletion And Amortization $336.0K $200.0K $100.0K
YoY Change 13.13% 100.0% 0.0%
Cash From Operating Activities -$7.965M -$10.63M -$13.35M
YoY Change -37.25% -20.36% 56.14%
INVESTING ACTIVITIES
Capital Expenditures $41.00K -$62.00K -$157.0K
YoY Change -130.6% -60.51% 161.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$41.00K -$62.00K -$157.0K
YoY Change -69.4% -60.51% -99.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -17.00K 65.06M 8.072M
YoY Change -96.9% 705.97% 1777.21%
NET CHANGE
Cash From Operating Activities -7.965M -10.63M -13.35M
Cash From Investing Activities -41.00K -62.00K -157.0K
Cash From Financing Activities -17.00K 65.06M 8.072M
Net Change In Cash -8.023M 54.36M -5.435M
YoY Change -40.02% -1100.26% -82.29%
FREE CASH FLOW
Cash From Operating Activities -$7.965M -$10.63M -$13.35M
Capital Expenditures $41.00K -$62.00K -$157.0K
Free Cash Flow -$8.006M -$10.57M -$13.19M
YoY Change -36.26% -19.88% 55.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Central Index Key
EntityCentralIndexKey
0001625101
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
plse Less Adjustment For Inventory At Cost
LessAdjustmentForInventoryAtCost
CY2021Q3 plse Less Adjustment For Inventory At Cost
LessAdjustmentForInventoryAtCost
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
CY2021Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
CY2021Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
CY2022Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
CY2022Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34899
dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5696597
dei Entity Address Address Line1
EntityAddressAddressLine1
3957 Point Eden Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
906-4600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
PLSE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37228200
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69162000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28614000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
61000
CY2022Q3 us-gaap Inventory Net
InventoryNet
750000
CY2021Q4 us-gaap Inventory Net
InventoryNet
5824000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1244000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2131000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
71161000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36630000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2286000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2462000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2717000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3216000
CY2022Q3 us-gaap Goodwill
Goodwill
2791000
CY2021Q4 us-gaap Goodwill
Goodwill
2791000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8250000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8785000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2022Q3 us-gaap Assets
Assets
87570000
CY2021Q4 us-gaap Assets
Assets
54249000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2022000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2904000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3982000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4389000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
38000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
858000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
436000
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
98000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6998000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8519000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9383000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10040000
CY2022Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
65000000
CY2022Q3 us-gaap Liabilities
Liabilities
81381000
CY2021Q4 us-gaap Liabilities
Liabilities
18559000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37228000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37228000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29716000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29716000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
37000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
291660000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
271861000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-285508000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236200000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6189000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
35690000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87570000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54249000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
574000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
574000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
8400000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
727000
us-gaap Cost Of Revenue
CostOfRevenue
10653000
us-gaap Cost Of Revenue
CostOfRevenue
727000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4517000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6460000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16744000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22982000
CY2022Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2020000
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3404000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
11251000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10697000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3088000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4256000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11373000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13772000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
18025000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
14847000
us-gaap Costs And Expenses
CostsAndExpenses
50021000
us-gaap Costs And Expenses
CostsAndExpenses
48178000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18025000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14273000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49312000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47604000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-14000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-9000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-640000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-640000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18039000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14282000
us-gaap Net Income Loss
NetIncomeLoss
-49308000
us-gaap Net Income Loss
NetIncomeLoss
-48244000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18039000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14282000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49308000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48243000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37158000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37158000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29612000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29612000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32825000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32825000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27400000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27400000
us-gaap Net Income Loss
NetIncomeLoss
-49308000
us-gaap Net Income Loss
NetIncomeLoss
-48244000
us-gaap Depreciation
Depreciation
520000
us-gaap Depreciation
Depreciation
349000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
499000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Share Based Compensation
ShareBasedCompensation
4443000
us-gaap Share Based Compensation
ShareBasedCompensation
10990000
us-gaap Inventory Write Down
InventoryWriteDown
7371000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-13000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-56000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
72000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2297000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4281000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-940000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2087000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
53000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-32000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-535000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-484000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-895000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
975000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-407000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-355000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
22000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-573000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
485000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-365000
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
98000
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
629000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
22000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39048000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41403000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
360000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
303000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-360000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7697000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
810000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
15000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4217000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
678000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14893000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56697000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
65000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1939000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
232000
us-gaap Repayments Of Debt
RepaymentsOfDebt
437000
us-gaap Repayments Of Debt
RepaymentsOfDebt
875000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
79956000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63234000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
40548000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
29528000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28614000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12463000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69162000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41991000
plse Increase Decrease In Equipment Purchases Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
-16000
plse Increase Decrease In Equipment Purchases Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
14000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
1000
us-gaap Stock Issued1
StockIssued1
629000
plse Stock Issuance Costs Accrued
StockIssuanceCostsAccrued
-29000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23415000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
113000
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
25000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
723000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18039000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6189000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
35690000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
136000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14864000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
486000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4443000
us-gaap Net Income Loss
NetIncomeLoss
-49308000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6189000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
389000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1577000
CY2021Q3 plse Adjustments To Additional Paid In Capital Debt Extinguishment And Private Placement Additional Issuance Costs
AdjustmentsToAdditionalPaidInCapitalDebtExtinguishmentAndPrivatePlacementAdditionalIssuanceCosts
47000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14282000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47387000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
plse Payment Of Stock Issuance And Debt Extinguishment Costs
PaymentOfStockIssuanceAndDebtExtinguishmentCosts
100000
plse Issuance Of Common Stock As Part Of Debt Extinguishment And Private Investment Net Of Issuance Cost
IssuanceOfCommonStockAsPartOfDebtExtinguishmentAndPrivateInvestmentNetOfIssuanceCost
49894000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3334000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7432000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
810000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-232000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10990000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Net Income Loss
NetIncomeLoss
-48244000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47387000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
107000
CY2021Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
27000
CY2022Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
107000
CY2021Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
27000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the condensed consolidated financial statements. Estimates include, but are not limited to, the valuation of cash equivalents, the valuation and recognition of share-based compensation, inventory valuation, warranty obligations, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. </span></p>
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7200000
us-gaap Inventory Write Down
InventoryWriteDown
7400000
CY2022Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
122000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
80000
CY2021Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
27000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
42000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
27000
CY2022Q3 plse Less Adjustment For Inventory At Cost
LessAdjustmentForInventoryAtCost
15000
plse Less Adjustment For Inventory At Cost
LessAdjustmentForInventoryAtCost
15000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13017965
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6023512
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
66551000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23675000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2010000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1371000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
750000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2443000
CY2022Q3 us-gaap Inventory Net
InventoryNet
750000
CY2021Q4 us-gaap Inventory Net
InventoryNet
5824000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5202000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4858000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2916000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2396000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2286000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2462000
CY2022Q3 us-gaap Depreciation
Depreciation
200000
CY2021Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
300000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5268000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4769000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2717000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3216000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
166000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
665000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
665000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
556000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2717000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2834000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2932000
CY2022Q3 plse Controlled Launch
ControlledLaunch
205000
CY2021Q4 plse Controlled Launch
ControlledLaunch
534000
CY2022Q3 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
123000
CY2021Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
245000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
178000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
85000
CY2022Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
107000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
80000
CY2022Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
326000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
209000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
513000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3982000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4389000
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
200000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
723000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1577000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4443000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10990000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
723000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1577000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4443000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10990000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
452000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1845000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1910000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1977000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2046000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6191000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14421000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4180000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10241000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
858000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9383000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10241000
us-gaap Operating Lease Payments
OperatingLeasePayments
1353000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M2D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
plse Number Of Kols
NumberOfKols
70
plse Number Of Patients Participating In Procedure
NumberOfPatientsParticipatingInProcedure
40 or 50
CY2022Q3 plse Program Expenses
ProgramExpenses
0
CY2021Q3 plse Program Expenses
ProgramExpenses
600000
plse Program Expenses
ProgramExpenses
600000
plse Program Expenses
ProgramExpenses
1200000
plse Controlled Launch Revenue Recognized
ControlledLaunchRevenueRecognized
400000
CY2022Q3 plse Additional Purchase Agreements
AdditionalPurchaseAgreements
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
700000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
574000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
574000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
574000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
574000

Files In Submission

Name View Source Status
0001625101-22-000067-index-headers.html Edgar Link pending
0001625101-22-000067-index.html Edgar Link pending
0001625101-22-000067.txt Edgar Link pending
0001625101-22-000067-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plse-20220930.xsd Edgar Link pending
plse-20220930x10q.htm Edgar Link pending
plse-20220930xex31_1.htm Edgar Link pending
plse-20220930xex31_2.htm Edgar Link pending
plse-20220930xex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
plse-20220930_cal.xml Edgar Link unprocessable
plse-20220930_def.xml Edgar Link unprocessable
plse-20220930_lab.xml Edgar Link unprocessable
plse-20220930_pre.xml Edgar Link unprocessable
plse-20220930x10q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending